Douglas Loe

Leede Jones Gable

Image: Douglas Loe

Douglas Loe, managing director and analyst at Leede Jones Gable, brings more than a decade of experience to financial analysis in the global drug development, medical technology, healthcare services and specialty pharmaceutical sectors. Loe has been recognized as one of Canada's top healthcare analysts by the StarMine Analysts Awards, based on the quality of his recommendations to institutional investors. He holds a Ph.D. in biochemistry.

Recent Articles

Testing Confirms Drug Candidate Differs From Peers 08/10/2022

Biotech ProMIS Neurosciences Inc.'s monoclonal antibody in development for Alzheimer's disease boasts a "unique" binding profile that could be "important to its clinical success," noted a Leede Jones Gable report.


Recent Quotes

"RHT added 50 new nursing home clients in Florida to its network."

— Douglas Loe, Leede Jones Gable (11/4/22)
more >

"PMN peer, Eisai, reported positive Phase 3 Alzheimer's disease data."

— Douglas Loe, Leede Jones Gable (9/30/22)
more >

"We are positive about PMN's PMN-310 possibly mitigating AD progression."

— Douglas Loe, Leede Jones Gable (9/28/22)
more >

"Experiments showed that PMN's PMN310 has a unique binding profile."

— Douglas Loe, Leede Jones Gable (8/5/22)
more >

"PMN's PMN310 could benefit from favorable FDA review of lecanemab."

— Douglas Loe, Leede Jones Gable (7/6/22)
more >

"We are initiating coverage on PMN with a Speculative Buy rating."

— Douglas Loe, Leede Jones Gable (5/11/22)
more >

"Liquidity metrics in Q2/18 indicated RP exited with cash of $48.8K."

— Douglas Loe, Echelon Wealth Partners (9/6/18)
more >

"RP signed on its licensing and codevelopment deal with YOFOTO."

— Douglas Loe, Echelon Wealth Partners (7/12/18)
more >



Due to permission requirements, not all quotes are shown.